专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20220340641A1 KRAS VARIANT MRNA MOLECULES 有权
公开(公告)号：US20220340641A1
公开(公告)日：2022-10-27
申请号：US17413654
申请日：2019-12-06
申请人： CureVac AG
发明人： Amit AGGARWAL , Katja FIEDLER , Ulrike GNAD-VOGT , Regina HEIDENREICH , Mythili KONERU , Gregory D. PLOWMAN
IPC分类号： C07K14/74 , C07K14/705 , A61K47/18 , A61K47/24 , A61K47/28 , C12N15/62 , C12N9/14
摘要： The present invention provides an mRNA molecule encoding at least one KRAS variant peptide. Further, the invention provides a pharmaceutical composition and kit comprising the mRNA molecule. The mRNA molecule, pharmaceutical composition and kit are useful for treating cancer.

2. 发明申请

US20190185859A1 RNA FOR CANCER THERAPY 审中-公开
公开(公告)号：US20190185859A1
公开(公告)日：2019-06-20
申请号：US16326281
申请日：2017-08-14
申请人： CureVac AG
发明人： Mariola FOTIN-MLECZEK , Aleksandra KOWALCZYK , Regina HEIDENREICH , Ulrike GNAD-VOGT , Ute KLINKHARDT , Katja FIEDLER
IPC分类号： C12N15/117 , A61P35/00 , A61K9/00 , A61K31/7088 , A61K39/395 , A61K38/20 , A61K38/17 , A61K39/39 , A61K39/00
CPC分类号： C12N15/117 , A61K9/0019 , A61K31/7088 , A61K38/177 , A61K38/208 , A61K39/0011 , A61K39/39 , A61K39/3955 , A61K2039/505 , A61K2039/53 , A61K2039/54 , A61K2039/55538 , A61K2039/572 , A61K2039/585 , A61P35/00 , C12N2310/17 , C12N2310/334 , C12N2310/336 , C12N2310/3513 , C12N2320/32
摘要： The present invention relates to RNA, particularly an immunostimulatory RNA (isRNA), a coding RNA or a combination thereof, for use in the treatment or prophylaxis of a disease, in particular a tumor and/or cancer disease. The present invention also provides pharmaceutical compositions, and a kit comprising the RNA(s). Further, the invention also comprises medical uses of the RNA(s) and compositions comprising the RNA(s).

3. 发明申请

US20220396796A1 RNA FOR CANCER THERAPY 有权
公开(公告)号：US20220396796A1
公开(公告)日：2022-12-15
申请号：US17571893
申请日：2022-01-10
申请人： CureVac AG
发明人： Mariola FOTIN-MLECZEK , Aleksandra KOWALCZYK , Regina HEIDENREICH , Ulrike GNAD-VOGT , Ute KLINKHARDT , Katja FIEDLER
IPC分类号： C12N15/117 , A61K38/20 , A61K39/00 , A61P35/00
摘要： The present invention relates to RNA, particularly an immunostimulatory RNA (isRNA), a coding RNA or a combination thereof, for use in the treatment or prophylaxis of a disease, in particular a tumor and/or cancer disease. The present invention also provides pharmaceutical compositions, and a kit comprising the RNA(s). Further, the invention also comprises medical uses of the RNA(s) and compositions comprising the RNA(s).

4. 发明申请

US20160168227A1 COMPOSITION AND VACCINE FOR TREATING LUNG CANCER 审中-公开
标题翻译：用于治疗肺癌的组合物和疫苗
公开(公告)号：US20160168227A1
公开(公告)日：2016-06-16
申请号：US15048216
申请日：2016-02-19
申请人： CureVac AG
发明人： Karl-Josef KALLEN , Mariola FOTIN-MLECZEK , Ulrike GNAD-VOGT
IPC分类号： C07K14/705 , A61N5/10 , A61K39/00 , A61K45/06 , C07K14/47 , A61K31/713
CPC分类号： C07K14/705 , A61K31/713 , A61K39/0011 , A61K45/06 , A61K2039/53 , A61N5/10 , C07K14/4727 , C07K14/4747 , C07K14/4748
摘要： The present invention relates to a composition comprising at least one mRNA encoding a combination of antigens capable of eliciting an (adaptive) immune response in a mammal, wherein the antigens are selected from the group consisting of 5T4 (Trophoblast glycoprotein, TPBG), Survivin (Baculoviral TAP repeat-containing protein 5; BIRC5), NY-ESO-1 (New York esophageal squamous cell carcinoma 1, CTAG1B), MAGE-C1 (Melanoma antigen family C1), MAGE-C2 (Melanoma antigen family C2), and MUC1 (Mucin 1). The invention furthermore relates to a vaccine comprising at least one mRNA encoding such a combination of antigens, and to the use of said composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, preferably of non-small cell lung cancer (NSCLC), and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the composition and/or the vaccine.
摘要翻译：本发明涉及一种组合物，其包含编码能够在哺乳动物中引发（适应性）免疫应答的抗原组合的至少一种mRNA，其中所述抗原选自5T4（滋养层糖蛋白，TPBG），存活蛋白（ MAGE-C1（黑素瘤抗原家族C1），MAGE-C2（黑素瘤抗原家族C2）和MUC1蛋白5（BIRC5），NY-ESO-1（纽约食管鳞状细胞癌1，CTAG1B）（粘蛋白1）。本发明还涉及包含至少一种编码抗原组合的mRNA的疫苗，以及所述组合物（用于制备疫苗）和/或疫苗用于引发（适应性）免疫应答的用途治疗肺癌，优选非小细胞肺癌（NSCLC）以及与之相关的疾病或病症。最后，本发明涉及试剂盒，特别涉及含有组合物和/或疫苗的试剂盒。

5. 发明申请

US20160166668A1 COMPOSITION AND VACCINE FOR TREATING PROSTATE CANCER 审中-公开
标题翻译：用于治疗前列腺癌的组合物和疫苗
公开(公告)号：US20160166668A1
公开(公告)日：2016-06-16
申请号：US15048126
申请日：2016-02-19
申请人： CureVac AG
发明人： Karl-Josef KALLEN , Mariola FOTIN-MLECZEK , Ulrike GNAD-VOGT , Thomas LANDER
IPC分类号： A61K39/00 , C07K14/47 , C12N9/16 , C12N9/64 , C12N9/48 , C07K14/705 , C12N9/02
CPC分类号： A61K39/0011 , A61K48/00 , A61K2039/53 , C07K14/4727 , C07K14/705 , C12N9/0091 , C12N9/16 , C12N9/485 , C12N9/6424 , C12Y116/01 , C12Y301/03002 , C12Y304/17021 , C12Y304/21077
摘要： The present invention relates to a composition comprising at least one mRNA encoding a combination of antigens capable of eliciting an (adaptive) immune response in a mammal, wherein the antigens are selected from the group consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific Membrane Antigen), PSCA (Prostate Stem Cell Antigen), STEAP (Six Transmembrane Epithelial Antigen of the Prostate), MUC1 (Mucin 1) and PAP (Prostatic acid phosphatase). The invention furthermore relates to a vaccine comprising at least one mRNA encoding such a combination of antigens and to the use of said composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (PCa), preferably of prostate adenocarcinoma, locally limited, locally advanced, metastatic, castration-resistant (hormone-refractory), metastatic castration-resistant and non-metastatic castration-resistant prostate cancers, and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the composition and/or the vaccine.
摘要翻译：本发明涉及一种组合物，其包含编码能够在哺乳动物中引发（适应性）免疫应答的抗原组合的至少一种mRNA，其中所述抗原选自PSA（前列腺特异性抗原），PSMA（前列腺特异性膜抗原），PSCA（前列腺干细胞抗原），STEAP（前列腺的六个跨膜上皮抗原），MUC1（粘蛋白1）和PAP（前列腺酸性磷酸酶）。本发明还涉及包含至少一种编码抗原组合的mRNA和用于所述组合物（用于制备疫苗）和/或用于引发用于治疗的（适应性）免疫应答的疫苗）的疫苗的疫苗的前列腺癌（PCa），优选前列腺腺癌，局部限制的，局部晚期的，转移的，去阉割的（激素难治的），转移性去阉割抗性和非转移性去钙抗性前列腺癌，以及与之相关的疾病或病症。最后，本发明涉及试剂盒，特别涉及含有组合物和/或疫苗的试剂盒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式